Drugs / Lactobacillus sakei proBio65
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05427695 | Feb 2025 → Mar 2028 expected | chronic rhinosinusitis | University of Illinois at Chicago | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lactobacillus sakei proBio65 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05427695 ↗ |
| Action | Restore | “In doing so, topical probiotics restore the commensal microbiome.” NCT05427695 ↗ |
| Modality | Other / unclassified | “probiotic” NCT05427695 ↗ |
| Route | Other | “Patients will perform nasal irrigation with Lactobacillus sakei” NCT05427695 ↗ |